Translating world leading research in NMT into a pipeline of first-in-class ADC medicines for cancer
Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival.
Investors
A private company, Myricx is backed by a strong syndicate of experienced life science and healthcare investors including Abingworth, Brandon Capital, British Patient Capital, Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, and Sofinnova Partners.
Location
Myricx is located within state-of the art office and laboratory facilities at the London Innovation Centre and benefits from the wider Canary Wharf life sciences ecosystem and excellent biotech network.
